Index

Note: Page numbers with f and t refer to figures and tables respectively.

AABB. See American Association of Blood Banks (AABB)
Abdominal laparoscopy, 424
Abdominal prostatectomy, reduction in blood loss in, 426
Abnormal coagulation tests, 93
ABO blood groups, discovery of, 3
ACE inhibitors, in HF, 232
Acid citrate dextrose, 4
Activated clotting time (ACT), 257
Activated partial thromboplastin time (aPTT), 256, 314
and prothrombin time test assessment, 257–8
monitoring of, 320
treatment of, 322
Active hemorrhage, fluid administration, 435
Actual blood loss (ABL), 306
Acute anemia, signs of, 509
Acute coronary syndrome
anemia and, 234–6
blood transfusion in, 75
Acute event-related anemia (AERA), 337
Acute isovolemic anemia, 299
Acute isovolemic hemodilution, tolerance to, 441
Acute lung injury (ALI), 175
Acute normovolemic hemodilution
(ANH), 220, 504–5
benefits of, 439
blood conservation strategy, development of, 446
and cardiac patient, 441–2
effects of anesthesia, 440–41
efficacy, 444–6
and hemostasis, 442–3
monitoring, 444
physiological compensatory mechanisms, 439–40
practical aspects, 443
safety for, 505
technique, 443–4
Acute respiratory distress syndrome
(ARDS), 175, 323
Addox, 386
Adenine, 11
Adenosine diphosphate (ADP), 262, 393
Adjuvative strategies, for blood transfusion
in cardiac surgery, 408
liberal reopening strategy, 408–9
mediastinal packing, 414–15
reopening and tamponade, clinical relevance of, 409–11
skeletalization of internal thoracic artery, 413–14
warm mediastinal irrigation, 412–13
Adult cardiac surgery, incidence of reopening, 409
"Advance Medical Directive/Release" card, 540
Advanced coagulation support, monitoring for, 256
Advanced Event Reporting System (AERS), 288
Aggressive phlebotomy, 350
Air embolism, avoidance of, 464
Albumin, 4–5, 96, 113
administration, rationale for, 97
Cochrane meta-analysis on, 101–2, 102t
consensus conferences on use of, 103
epidemiological surveys on use of, 102–3
extraction, 97
manufacturing of, solutions of, 97–8
physiology, 96–7
and plasma COP, 96
role of, 96–7
solutions, clinical uses of, 98
COP, management of, 99
hypoaalbuminemia, treatment of, 98–9
in infants and neonates, 100
for meeting fluid demands in critically ill patients, 99
other usages, 100–101
in trauma and sepsis, 99–100
for treatment of burns, 100
synthesis, 96–7
use of, in ICU patients, 168, 170
Algebraic approach, for blood loss, 305
Allergic and anaphylactic reactions, 343
Allogeneic and autologous blood
| cost-effectiveness of, 563 |
| cost utility of autologous and allogeneic blood, comparison of, 563–4, 564f |
| methods for, 563 |
| studies on, limitations of, 564–5 |
| cost of, 559–60 |
| consensus cost elements in, 560–61, 561f |
| literature on, 561–2 |
| studies on, limitations of, 562–3 |
Allogeneic blood components
apheresis collections, 12
donor selection and testing and, 11
irradiation of, 18
for IUT and for neonatal transfusion, 19–20
leukocyte depletion of, 12–13, 13t
preparation and storage of frozen-plasma components, 16, 17t
granulocytes, 18
platelet components, 15–16
red-cell components, 13–15
and prion removal, 19
quality monitoring of, 18
whole blood collection, storage, and processing, 11–12, 12f
Allogeneic blood transfusion (ABT), 498, 513
alternatives to, 6
autologous transfusion, 6–7
fibrin sealants, 7
hemostatic agents, 7
pharmacologic alternatives, 7
red cell substitutes, 7
costs and risks reduction, 450–51
effects of, 421
efficacy of ANH in reducing, 442–3
outcomes, in total joint replacement patients, 353t
in patients, 571f
of RBC, 298, 322
rFVIIa in reducing, 279
risk of, 317, 380, 459
usage of, 499
Allogeneic RBC transfusions, for anemia of prematurity, 492f
Allowable blood loss and minimally tolerated hematocrit, relationship of, 306

Alternatives to allogeneic transfusion (AAT), 499. See also Allogeneic blood transfusion (ABT)

American Association of Blood Banks (AABB), 5, 42, 218, 525
code, 526
standards, 526

The American College of Surgeons Classes of Acute Hemorrhage, 163

American Medical Association (AMA), 523

American Red Cross Blood Donor Service, 526

American Society of Anesthesiologists (ASA), 316, 434
guidelines for RBCs transfusion, 219t

Amotosalen approach, 61

Amotosalen-treated plasma, 63

Anaphylactic transfusion reactions, 39–40

Anemia, 509. See also Erythrocyte transfusion, benefits of algorithm for management, 338f

benefits of treatment, 238–9

biochemical characteristics of, 480t

in cardiovascular disease, 229–31

and acute coronary syndromes, 234–6

cardiac disorders, 238

and chronic renal disease, 236

pathophysiological mechanisms, 230f

causes of, 479f

characteristics of, 357

of chronic disease, 338–9

clinical features of, 510–11

in critical illness, prevalence of, 477

definition of, 477, 509

diabetes, 239–40

donor blood transfusions, 516

risks of, 516

erythropoietin therapy for, 348–9, 349t

etiology of blood loss, 479–80

hemodilution, 479

reduced red cell production, 480–82

reduced red cell survival, 480

factors for, 482

forms of, 509

in heart failure

correction treatment, 233–4

mechanisms of, 231–3

prevalence and prognostic implications, 231

HV effects on cognitive function and iron deficiency, 333

iron saccharate complex, usage of, 514

management of erythropoietin therapy, 485–6

RBC transfusion, 482–5

red cell loss, reduction of, 482

noniron deficiency, 339

oral iron, role of, 512–13

parenteral iron sucrose complex, 513

perioperative anemia

iron for treatment, 340, 344

pathophysiological mechanisms in, 337f

and postoperative morbidity and mortality risk, 297

postpartum, 514–15

preexisting fetal risks, 511–12

maternal risks, 511

in pregnancy

and postpartum period, 513–14

treatment of iron-deficiency, 512

of prematurity. See also Red blood cells

(ABC), 12

Antibody-mediated PRCA, 361

Angiotensin II, 232

Angiotensin-converting enzyme (ACE) inhibitors, 361

Antihypertensive agents, 7

in orthopedic surgery, 502. See also Orthopedic surgery safety, 502

usage of, 576

Antithrombin III (AT III) deficiency, 94

Antithrombotic therapy, in open-heart surgery

aprotinin, 271–3

clinical outcomes, 270–71

hemostasis activation in CPB, 268

lysin analogs, 269–70

mode of action of aprotinin, 268–9

prophylactic administration of, 267

Antilipolytics tranexamic acid, 269

Antigenicity, of aprotinin, 272–3

Antiplatelet agents

Aprotinin, 271–3

in open-heart surgery, 271

Arm cleansing methods, use of, 28

Arterial oxygen content (CaO2), 211

definition of, 451

expression of, 220

hypoxic ventilation, 451–2

increase of, 450

measurement of, 298

and oxygen delivery, 205

Arterial thrombotic events, incidence of, 286

Aseptic technique, importance of, 443

Atrial septum defect (ASD), 571–2

Augmented oxygen delivery, theory of, 383

Autologous blood

and cell salvage, 458

collection and transfusion of, 349t

transfusion of, 444

Autologous blood donation (ABD), 348

current status of, 348

erythropoietin therapy, 348–9

Autologous blood in orthopedic surgery

usage of

ANH, 504–5

PABD, 503–4

PRCS, 504

Autologous blood predonation, in cardiac surgery

cost-effectiveness of, 569–70

efficacy of, 572

experiences and outcomes of center with, 570–72
Autologous predonation, usage of, 563
Autologous transfusion, 6–7
Autologous whole blood (AWB), 306

*Babesia divergens*, 23
*Babesia microti*, 23
Bacterial contamination, 27–8
in cell salvage, 466
Balanced salt solutions, 112–13, 112t, 198
B12 and folate metabolism, in intensive care patients, 481. See also Anemia
β-blockers, role of, 237
Belgian study, on plasma transfusions, 96
B12/folate deficiency anemia, characteristics of, 339
Bill of Rights of the Constitution of the United States, 531
B19 infection, 65
Bioactive contaminants, in unwashed wound blood, 460t
Biodegradable nanocapsules, 375
Bis (3,5 dibromosalicyl) fumarate (DBBF), 370
Bivariant analysis, of blood loss, 304–5
Bleeding
effect of resuscitation fluid on, 179, 182
history, preoperative assessment of, 255
impact of, 408
minimized extra-corporal circulation effect, 402t
robotic and video-assisted valve surgery impact, 399t
tendency and inflammatory reactions, reduction of, 267
Bleeding time (BT), 316–17
usefulness of, 319–20
in vivo, 262
Blood banks, establishment of, 4
Blood-biomaterial interaction, of
Blood cell separators, 5
Blood conservation
in cardiac surgery, 408
efficacy of ANH, 445
minimally invasive cardiac surgery effect, 392
strategy development, ANH in, 446
Blood-conservation techniques, 73
Blood Conservation using
Antifibrinolytics: A Randomized Trial (BART), 273
Blood cost literature, 561–2. See also Allogeneic and autologous blood
“Blood scarcity”, 5
Blood flow
heterogeneity, 210
in microcirculation, 210–11
Blood gas analysis, 256
Blood irradiation, effectiveness, 466
Blood lactate concentrations, 212
Bloodless medicine and surgery, 544
Blood loss. See also Anemia; Orthopedic surgery
and anemia, 479–80
in anesthetized patients, factors for, 421
blood sampling, 479
estimation
bivariant analysis of, 304–5
calculus/computer model validation, 309–10
complication of, 303
computer modeling, 309
phases in, 306–8
univariant analysis of, 303–4
fluid replacement of surgical, 450–51
hemorrhage, 479–80
intraoperative surgical, 450
minimal fractional, calculation, 444–5
in orthopedic surgery, reduction of, 502
reduction
abdominal prostatectomy in, 426
anesthetic techniques, 421–7
controlled hypotension in, 432–3
epidural anesthesia in, 426
through hemostasis preservation, 319
Blood pressure, effect of HS/HSD on, 185
Blood product administration and fluid resuscitation, 321f
Blood products, safety of, 6
Blood refusal card, 544
Blood replacement, in human, 368
Blood salvage, 458
advantages of, 467–9
application of, 465
intraoperative, 464, 466
quality management, 467
Blood saving by retransfusion, cell salvage in, 468
Blood sparing technique, 451f
Blood stream, emulsion microdroplets, movement in, 383
Blood transfusion, 3, 527
adverse effects of, 236
in anemic patients with ACS, 235–6
blood collection for, 5
and blood components separation technique, 3–6
in cardiac surgery, adjunctive strategies, 408
liberal reopening strategy, 408–9
mediastinal packing, 414–15
reopening and tamponade, clinical relevance of, 409–11
skeletization of internal thoracic artery, 413–14
warm mediastinal irrigation, 412–13
causes and risk factors for, 511t
on cellular oxygenation, 206
delay, HV effects on, 455
effects on oxygen extraction, 207
historical perspectives of, 295–6
history of
blood banks, institution of, 4
and donor recruitment techniques, 4
laboratory phase, 3–4
surgical phase, 3
world wars, and developments, 4–5
microcirculatory effects of, 207–8
in obstetrics
causes and risk factors for, 511t
donor blood transfusions, 516
maintaining fluid balance, 516–17
prescribing donor blood, considerations in, 516
and safety of blood products, 6
on tissue oxygenation, evaluation, 224t
Watchtower Society’s views on, 545
Blood usage, prediction of, 303–4
Blood volume
collection, calculation, 443
importance of, 296
Blunted erythropoiesis, causing anemia, 337
Bone marrow suppression, 480
*Borrelia burgdorferi* (Lyme disease), 23
Bovine free Hb, 370
Brain injury and coagulopathy, 315
British Committee for Standards in Haematology, 42
*Brucella melitensis* (brucellosis), 23
B-type natriuretic peptide (BNP), 233
Burns, blood transfusion in, 75
Bystander hemolysis, 33
C3 activation, 38
Calculus approach, for blood loss, 306
validation of, 309–10
Cancer development, intravenous iron and, 344
Cancer surgery, cell salvage in, 465–6
Cardiac disorders and anemia, 238
Cardiac dysfunction, development of, 442
Cardiac index (CI)
and O2/ER relationship, transfusions effects, 207f
and oxygen extraction, 211
Cardiac output
decrease of, 206
increase in, 439–40
and oxygen delivery, 205
Cardiac patient and acute normovolemic hemodilution, 441–2
Cardiac surgery, 267
adjunctive strategies for blood transfusion in, 408
liberal reopening strategy, 408–9
mediastinal packing, 414–15
reopening and tamponade, clinical relevance of, 409–11
skeletization of internal thoracic artery, 413–14
warm mediastinal irrigation, 412–13
Cardiac surgery (Cont.)
  autologous blood predonation in, 569
  cost-effectiveness of, 569–70
  efficacy of, 572
  experiences and outcomes of center
  with, 570–72
  blood conservation in, 408
  cell salvage in, 464
  clinical results of antifibrinolytics,
  270–71
  economic evaluations in, 578
  lysine analogs in, 269–70
  minimally invasive; 392
  MIDCAB, 396
  OPCAB, 394, 396
  videoendoscopic and robotic-assisted
  nonsternotomy approaches, 396–8
  pharmacologic treatment alternatives in,
  576
  transfusion incidence, 391–2
Cardiac surgery study, of preoperative
anism, 73
Cardiopulmonary bypass (CPB), 383, 392
  activation of hemostasis, 268
  bleeding and nonhematic fluids, 240
  characteristics of, 267
  in myocardial necrosis reduction, 373
  use of rFVIIa in, 279
Cardiorenal anemia syndrome, 231–2,
  232L, 236
Cardiorespiratory parameters, monitoring
of, 444
Cardiovascular disease (CVD) and anemia,
  229–31
  and acute coronary syndromes, 234–6
  cardiac disorders, 238
  and chronic renal disease, 236
  in heart failure
  correction treatment, 233–4
  mechanisms of, 231–3
  prevalence and prognostic
  implications, 231
  pathophysiologic mechanisms, 230f
CardioVations, 400f
Cell-free oxygen carriers, 369
Cell salvage syndrome, 461
Definition of, 458
  intra and postoperative
  advantages of, 467–9
  bacterial contamination, 466
  surgery, 465–6
  cardiac surgery, 464
  cell separation and washing, 460–64
  obstetrics, 466–7
  orthopedic surgery, 464–5
  pediatric surgery, 465
  polytrauma, 465
  quality management, 467
  vascular surgery, 465
Cellular oxygenation, blood transfusions
  effects, 206
  Centers for Disease Control and
  Prevention, 77
  Central Institute of Hematology, Russia, 4
  Central nervous block, 432
  Central venous O₂ saturation (ScvO₂),
  211
  Cerebral and coronary vasodilation, 440
  Cerebral edema, and use of Ringer’s
  lactate, 112
  Cerebral effects of controlled hypotension,
  study of, 433
  Chikungunya, 6, 23
  Chronic anemia
  and heart failure, 229
  signs of, 509
  Chronic disease, anemia of, 338–9
  Chronic HES nephrotoxicity, 151
  Chronic ischemic heart disease, patient
  with, 484
  Chronic kidney dysfunction (CKD), 231
  anemia and, 238, 357
  heart abnormalities in, 236–8
  Chronic renal disease and anemia, 236
  Chronic renal insufficiency, 231
  Citrate–phosphate–dextrose (CPD), 443
  Clauss method, 257
  Clopidogrel, 235
  Clot firmness defect, detection of, 258–9
  Coagulation
  factors, in coagulopathy, 316
  screening tests, use of, 320
  therapy, management algorithm for,
  260–61
  Coagulation disorders, FFP for, 92–3
  Coagulation factor VIII and vWF-lowering
  potency
  of gelatins and dextrans, 138
  mechanism for, 139–40
  Coagulation factors, average half-lives of,
  93t
  Coagulopathy
  monitoring of, 319–21
  and MT, variables for
  coagulation factors, 316
  cryoaloids and coloids, 318–19
  platelets, 314–16
  red cells, 316–18
  temperature, 319
  treatment of, 321–4
  Code of Ethics, usage of, 525
  Cohn alcohol extraction method, 97
  Colloid osmotic pressure (COP), 96, 159,
  173
  Colloids, 113–14
  choice of, in critically ill patients. See
  Intensive care patients, choice of
  colloid for
gelatins, 114
  monodisperse system, 113
  polydispersity system, 113
  number-averaged molecular weight,
  calculation of, 113
  weight-averaged molecular weight,
  calculation of, 113
  Colloids and cryoaloids, usage of, 443
  Component therapy, 5
  Computer modeling, for blood loss
  estimation, 309
  validation of, 309–10
  Congestive heart failure, 236
  Continuous AutoTransfusion System
  (CATS), 462
  principle of, 463f
  Continuous blood processing, 461
  Continuous erythropoiesis receptor
  activator (CERA), 358
  clinical use of, 360
  Controlled intraoperative hypotension,
  430
  approaches of, 430–32
  benefit of, 432–3
  in elective surgery, 434–5
  in resuscitation from hemorrhagic
  shock, 435–6
  risks of, 433–4
  Coombs test, 5, 37
  Cornstarch, 116
  Coronary artery bypass grafting (CABG),
  229, 396, 409, 564, 570–71
  anemia risk in, 240–41
  video/robotic-assisted, 398t
  Coronary artery disease (CAD), 221, 230
  Cost-effectiveness analysis (CEA), 563
  Cost utility analysis (CUA), 563
  advantage of, 563
  of autologous and allogeneic blood,
  563–4
  Coumadin, 92
  C-reactive protein (CRP), 237
  CREATE study, 239
  Creutzfeldt Jakob disease (CJD), 97
  Critical Hb level, 219–21
  Critical hemoglobin concentration, 482.
  See also Red blood cells (RBC)
  Critical ill patients
  anemia etiology in
  blood loss, 479–80
  hemodilution, 479
  reduced red cell production, 480–82
  reduced red cell survival, 480
  anemia prevalence in, 477
  biochemical characteristics of anemia in,
  480
  erythropoietin therapy in, 485–6
  hemoglobin concentration in, 482–4
  Critical oxygen delivery, 219–21, 299
  Cross-linked gelatin, 160
  CRUSADE trial, 235–6
  CRYCO Study Group, 130
  Cryoprecipitate, 16
  Cryoprecipitate-depleted plasma (CDP), 16
  Cryosupernatant plasma, 90
Index
586 Index

Ferumoxytol, 364
Fetal risks and iron deficiency, 511–12
Fibrinogen concentration test, 257
Fibrinogen, role of, 257, 314
Fibrin sealants, 7
in orthopedic surgery, 502–3
Fick method, 211
Fluid administration, in trauma patients, 435
Fluid replacement of surgical blood loss, 450–51
Fluid resuscitation. See also Intravenous fluids, pharmacology of
advantages/disadvantages of colloid- and crystalloid-based regimes, 121f
best strategy for, in major surgery, 129f
clinical goals of, 127–8
colloid-based fluid resuscitation, 121f, 126
disadvantages of, 127
hemorrhological effects of, 126–7
plasma volume supporting capacity of, 126
crystalloid resuscitation fluids, 121f, 122–3
disadvantages of, 124–6
distribution between fluid spaces, 123
crystalloid or colloids, use of in intensive care, 130
in surgery, 128–30
fluid spaces of body, 120–21, 121f
importance of, 119
optimal fluid regimen, controversy on, 120
practice in ICU, 131
trauma induced fluid fluxes, 121–2
Fluid resuscitation and administration of blood products, 321f
Fluorocarbon emulsions, 381–2
Fluosol-DA, 385
Food and Drug Administration (FDA), 288
Fractions of inspired oxygen (FiO2), 381
Fluorocarbon emulsions, 381–2
Fluid resuscitation. See also Intravenous fluids, pharmacology of
advantages/disadvantages of colloid- and crystalloid-based regimes, 121f
best strategy for, in major surgery, 129f
clinical goals of, 127–8
colloid-based fluid resuscitation, 121f, 126
disadvantages of, 127
hemorrhological effects of, 126–7
plasma volume supporting capacity of, 126
crystalloid resuscitation fluids, 121f, 122–3
disadvantages of, 124–6
distribution between fluid spaces, 123
crystalloid or colloids, use of in intensive care, 130
in surgery, 128–30
fluid spaces of body, 120–21, 121f
importance of, 119
optimal fluid regimen, controversy on, 120
practice in ICU, 131
trauma induced fluid fluxes, 121–2
Fluid resuscitation and administration of blood products, 321f
Fluorocarbon emulsions, 381–2
Fluosol-DA, 385
Food and Drug Administration (FDA), 288
Fractions of inspired oxygen (FiO2), 381
Fluorocarbon emulsions, 381–2
Functional iron deficiency (FID), 333, 481, 515
Functional Outcome in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), 500
Gas solubility by perfluorocarbons, 382
Gastric mucosal tonometry, 222–3
Gastric tonometry, 213
Gelatin-based plasma expander, effect of, 318
Gelatins, 114, 119, 138, 144
adverse effects of, 114
effect on coagulation, 114
polydispersity of, effects of, 114
types of succinylated gelatins, 114
urea-linked gelatin, 114
use of, in ICU patients, 170
Gelofusin®, 114
Global hemodynamic effects, 208
Global oxygen consumption, 298
Global oxygen delivery, 211, 298
Glomelural filtration rate (GFR), 236, 433–4
Glucuronate, use of, 112
Glues, in orthopedic surgery, 502–3
Granulocytes, preparation and storage of, 18
Haemaccel®, 114
Hamster scrapie models studies, 19
HBOCs. See Hemoglobin-based oxygen carriers (HBOCs)
Health care
DPA for, 547–55
economic evaluations in, 575–6
Hematopoietic stem cell (HSC), 526
Hem iron, absorption of, 334
Hemochromatosis, marrow response in, 350
Hemodilution
affecting hemostasis, ways of, 442–3
and anemia, 479
with crystalloid, 318
effects of anesthesia, 440
in heart failure, 232
hypertonic fluids and, 186–7
induced tissue hypoxia, 454
limits of, 441
Hemodynamic monitoring, in perioperative period, 444t
Hemoglobin-based oxygen carriers (HBOCs)
first generation of, 369–71
current status of, 371–4
meta-analysis, 375–6
and PFCs, 381
second generation of, 374–5
Hemoglobin (Hb)
based blood substitutes, 371t, 375–6
of first and second generation, properties of, 374t
problems with, 372t
concentration, in transfusion trigger determination
alternative to, 297–8
clinical conditions, 299–300
10/30 rule, 296
tolerable hemoglobin, 297
validation of, 300–301
effect of, 357–8
in erythrocytes, 368
free molecule sources of, 369–70
techniques to obtain, 369t
hyperoxic vasoconstriction in normal, 454
iron, 336
level, ESA dose and dialysis dose increase, relationship of, 360
loss, amount calculation of, 304
and perfluorocarbons, 380
toxicity, 368
Hemoglobin transfusion rates, in intensive care, 479t
Hemoglobinuria, 33
Hemolink®, 371, 373
Hemolytic transfusion reactions (HTR), 32–3
clinical signs and symptoms of, 35
delayed HTR (DHTR), 33
differential diagnosis of, 36t
investigation of, on AABB standards, 35–6
from non-red cell blood components, 33
pathophysiology
extravascular HTR, 34–5
intravascular HTR, 33–4
severe acute HTR (AHTR), 32–3
from transfused red cells, 32–3
treatment of, 36–7
Hemolytic uremic syndrome, 94
Hemopoietic growth factors, 7
Hemopure®, 371, 373
Hemorrhage, 206
and anemia, 479–80
treatment of, 287
Hemovigilance system, 7, 28
Hemostatic system
activation, in CPB, 268
and acute normovolemic hemodilution, 442–3
characteristics of primary, 315
effects of HES solutions, 318–19
erthrocytes modulation, 287
hemoglobin/hematocrit concentration
role, 317–18
perioperative monitoring of
intraoperative monitoring, 256, 261f
near-patient coagulation monitoring
deVICES, 258–62
platelet function tests, 262–3
preoperative evaluation and
preparation, 255–6
routine coagulation testing, 256–8
preoperative monitoring of, 256f
Hemostatic agents, 7
Hemostatic blood components, transfusion
of, 321
Hemostatic effects, of normovolemic
hemodilution, 317
Hemostatic system
changes to monitor, 319
pathways of, 268
Hemovigilance system, 7, 28
Hem receptor, 334
Heparin, 268, 393
Hepatic EPO, 268, 393
Hepatic platelet sequestration, 319
Hepatitis B virus (HBV), 21
Hepatitis C virus (HCV), 21
Heparin model, 336
HES-induced pruritus, 151
Hexadimethrin®, 116
High blood pressure, ESAs causing, 362
Hip replacement surgery (THR), 425–6
Hot water irrigation (HWI) for hemostasis,
412
Human albumin (IA), use of, 159–60
Human free Hb, 369–70
Human immunodeficiency virus (HIV), 21, 241
Human Prothrombin Complex, 92
Hydroxyethyl starch (HES), 114–16,
137–8, 144, 318, 382
adverse effects of, 116
classification of, 115–16, 171
effect of, on hemostasis, 139f
cogulation factor VIII and vWF, decrease in, 138
effect on fibrinolysis, 142
hypocogulability, 141–4
and limitations of study designs, 144–5
platelet inhibiting effect, 140–41
and reversing strategies, 144
suspension medium, effect of, 142
thrombin–fibrinogen interactions and
fibrin clot formation, decrease in, 142
and fluid therapy in intensive care, 153–5
induced nephrotoxicity, 150–51
and kidney transplantation, 151–2
and perioperative renal function,
152–3
potato-derived starches, 116
use of, in ICU patients, 171
Hydroxyurea, 76
Hyperchloremic acidosis, 111–12, 122,
142, 162, 187, 201
acid-base disturbances and
bicarbonate-centered approach to, 194
quantitative physicochemical
approach to, 194–8.
Stewart’s physicochemical
theory, of acid-base balance
consequences of
animal studies, 199
clinical studies, 200–201
in vitro studies, 199
volunteer studies, 199–200
etiology of, 198–9
Hypercoagulability, 143–4
Hypertension, 187
Hypochromic red blood cells (HbRC), 339, 363
Hyperoxic ventilation (HV), 450
Hypertonic saline (HS) solutions, use of
injuries.
Hyperoxic vasoconstriction, 452
Hyperoxic hemodilution, blood sparing
technique, 451f
Hyperoxic vasodilatation, 452
Hyperoxic ventilation (HV), 450
on arterial oxygen content and oxygen
delivery, 451–2
induced vasodilatation, 454–5
in red blood cell transfusion, 454–5
role of, 452
Hyperphosphatemia, 237
Hypertension, ESAs causing, 362
Hypertonic saline dextran (HSD), 180
Hypertrophy, 433
Hypertension, ESAs causing, 362
Hypertensive anemia, 427
Hypertensive
anesthesia, 427
resuscitation, 436
Hypothermia
causes of, 422
induced hemostatic defect, 322
role of, 319
Hypovolemia, 158–9, 168
correction of, 206
Iatrogenic sodium chloride overdose, and
hyperchloremic acidosis, 198
Iatrogenic tissue edema, 125
Ideal Hb-based blood substitute, definition
of, 368–9
IgA-deficient donors, 40
IL-6, 38
IL-8, 38
Imferon, 351
Immunological complications, of blood
transfusion, 31–2, 321
allergic and anaphylactic reactions,
39–40
FNHTR, 37–9
HTR, 32–7
immunological refractoriness to platelet
transfusions, 44–5
PTP, 43–4
TA-GVHD, 41–3
TRALI, 40–41
Impaired clot stability defect, detection of,
259
Inactine, 62
Incisions bleeding and transfusion
decrease, mechanism of, 259
Optimer, 259
Incisions bleeding and transfusion
decrease, mechanism of, 259
Incremental cost-effectiveness ratio
(ICER), 575
Induced hypotension, 431
Infection, intravenous iron and, 343
Index

588

Infectious risks, of allogeneic transfusion, 21–2
approaches for reducing of, 29
leukodpletion, 29
bacterial contamination, 27–8
clinical use of blood, 28–9
identifying transfusion-transmitted infections, 28
new or emerging infectious "threats," 23–4
residual risk, 25–6
data on, 26–7, 27t
estimates of, 26
screening, to reduce risk, 24. See also Screening program
donor selection process, 24
laboratory screening, 24–5
transfusion-transmissible infectious agents, 22–3, 22f
InFed, administration of, 351
Inflammation effects, on iron homeostasis, 336–7
Inflammatory bowel disease (IBD), 340
Inflammatory diseases and anemia, 337
Informed consent
donor, 526–7
ethical basis for, 524–5
historical background of, 523–4
in transfusion medicine, 525–6
Injury Severity Score, 315
Intensive care patients, choice of colloid for, 168
advantages of colloids, 169t
adverse effects of colloid use, 171t
acute fetal distress, 174
anaphylactic or anaphylactoid reactions, 171–2
coagulopathy, 174
disturbances in renal function, 173–4
in transfusion medicine, 525–6
Intravenous fluids, pharmacology of, 111
categories of, 111
coagulopathy, 174
disturbances in renal function, 173–4
fetal risks, 511–12
internal thoracic artery (ITA), 413
Intrauterine growth retardation (IUGR), 511
Intrauterine fetal death (IUFD), 511
Intrinsic compensatory mechanisms, 439
Iron absorption, 334
regulation, 336
Iron administration, approaches of, 363–4
Iron deficiency, 333, 498
Iron dextran, 352, 364
Iron distribution, 334–6
Iron gluconate
for iron deficiency, 341
usage of, 340–41
IRON-HF study, 234
Iron homeostasis, 333–4
inflammation effects on, 336–7
mean pathways of, 335f
Iron metabolism, in intensive care patients, 480–81. See also Anemia
Iron-refractory, iron-deficiency anemia (IRIDA), 337
Iron-responsive elements (IRE), 336
Iron-responsive proteins (IRP), 336
Iron saccharate, 351–2
Iron saccharate complex
usage of, 513–14
Iron storage, 336
Iron sucrose, usage of, 341–2, 364
Iron supplementation, in EPO therapy, 350
Iron therapy, 339–40
for anemia, 512
in EPO therapy, 350
in patients with renal failure, 362–4
for perioperative anemia, 340, 344
and rHuEPO, 342–3
Irradiation, of blood components, 18, 42,
61
Isoflurane, solubility of, 384
Isovolemic, usage of, 443
Isovolemic hemodilution, blood flow in, 440
Isovolemic hemodilution, 440–41, 443, 443t
Intention-to-treat principle, 287–8
Interdonor incompatibility, 33
Interleukin-6 production, 392
Internal thoracic artery (ITA), 413
International normalized ratio (INR), 257
International Society of Blood Transfusion (ISBT), 526
Intra and postoperative cell salvage
advantages of, 467–9
bacterial contamination, 466
cancer surgery, 465–6
cardiac surgery, 464
cell separation and washing, 460
adverse effects, 462–4
cost-effectiveness, 462
indications and contraindications, 464
methodologies of, 461
obstetrics, 466–7
orthopedic surgery, 464–5
pediatric surgery, 465
polytrauma, 465
quality management, 467
vascular surgery, 465
Intra-aortic balloon pump (IABP), 409
Intracerebrovascular hemorrhage (ICH), 285
Intracranial aneurysm surgery, 434
Intraluminal carbon dioxide, measurement, 222–3
Intramolecular cross-linking, of Hb, 370
Intravenous iron
agents, 340–42
and cancer development, 344
formulations, characteristics of, 341t
and infection, 343
and oxidant damage, 343–4
therapy
adverse effects of, 352
role for, 350–51
Intestinal ischemia
screening, 22
Intensive care unit (ICU), anemic patients in
blood loss in, 479–80
prevalence of, 478t
red cell transfusion in, 482–5
Intensive insulin therapy, effect of, 237
crystalloids, 111
balanced salt solutions, 112–13
normal saline, 111–12
hypertonic solutions, 113
Intravenous immunoglobulin (IVIg), use of, 36
Intravenous iron agents, 340–42
and cancer development, 344
Informed consent
for iron deficiency, 341
usage of, 340–41
Iron deficiency, 333, 498
diagnosis of anemia, 338
without anemia, 337–8
and preexisting anemia
fetal risks, 511–12
maternal risks, 511
Iron deficiency anemia (IDA), 338
Iron dextran, 352, 364
Iron distribution, 334–6
Iron gluconate
for iron deficiency, 341
usage of, 340–41
IRON-HF study, 234
Iron homeostasis, 333–4
inflammation effects on, 336–7
mean pathways of, 335f
Iron metabolism, in intensive care patients, 480–81. See also Anemia
Iron-refractory, iron-deficiency anemia (IRIDA), 337
Iron-responsing elements (IRE), 336
Iron-responsing proteins (IRP), 336
Iron saccharate, 351–2
Iron saccharate complex
usage of, 513–14
Iron storage, 336
Iron sucrose, usage of, 341–2, 364
Iron supplementation, in EPO therapy, 350
Iron therapy, 339–40
for anemia, 512
in EPO therapy, 350
in patients with renal failure, 362–4
for perioperative anemia, 340, 344
and rHuEPO, 342–3
Irradiation, of blood components, 18, 42,
61
Isoflurane administered concentration,
increase, 431
Isoflurane, solubility of, 384
Isovolemic, usage of, 443
Isovolemic hemodilution, blood flow in, 440
Jehovah’s Witnesses, 468, 531
activities and practices of, 531–2
belief on blood transfusions, 532
and bloodless medical treatment, 544
conflict with modern medicine, court
cases on, 532
Application of the President and
Directors of Georgetown College,
Inc., 533–4
Banks v. Medical University of South
Carolina, 543
Clark v. Perry, 540–41
George-town Hospital Case, 545
John F. Kennedy Memorial Hospital v.
Heston, 535
Jones v Wrona, 542
Perkins v. Lavin, 540–41
Prince v. Massachusetts, 543
Re Baby Bay Dee, 541
In re Fetus Brown, 541–2
In re Quinlan, 535
In re Rona, 542
Re v. Wade, 535
Sargent v. New York Infirmary-Beekman
Downtown Hospital, 542
Shine v. Vega, 542
Superintendent of Belcherton Hospital v.
Salkiewicz, 537
Werth v. Taylor, 538
“Health Care Proxy” forms by, 536, 546
and protection of rights of patients,
543–6
religious freedom, protection of, 531
Jehovah’s Witness hospital Liaison
Committees, 536, 544, 546
Kallikrein inhibiting units (KIU), 268
Kidney transplantation, and HES
solutions, 151–2
Knee replacement surgery, HES
administration, 318
Labeling, Plasma, 91
Lactate, production of, 212
Lambert–Beer law, 214
Laparoscopic cholecystectomy, 432
Laser doppler flowmetry, 452
LD filters failure, donor-related causes of,
13
Left anterior mini-thoracotomy, usage, 396
Left ventricular hypertrophy (LVH),
170–71
Lethal complications of unwashed blood
transfusion, 459
Leuconostoc mesenteroides, dextran from,
170–71
Leukocyte antibodies, and FNHTR, 37–8,
Recombinant human erythropoietin (rHuEPO), 499
goal of, 494
hemoglobin increase, 485
meta-analysis of, 486
in orthopedic surgical patients, 501
in RBC transfusions, 495
stimulation of erythropoiesis with, 515–16
Recombinant human erythropoietin (rHuEPO) therapy, 348
clinical trials of, 348–9
economic analysis of, 352–3
and erythropoietic response, 349–50
iron supplementation, 350
safety considerations of, 353
in surgical anemia, 349t
Recombinant human Hb, production of, 370
Recombinant technology, for hemoglobin, 370
Red blood cells (RBC), 477
in anemia of prematurity treatment neonatal, 494–6
pathophysiology of, 490–92
transfusions, 492–4
enzyme, coencapsulation of, 375
function of, 219
maturation, abnormal, 481–2
mean hematocrit of, 208
orthogonal polarization spectroscopy, 212–13
production in autologous blood donation, 351f
recovery, calculation, 467
transfusion, 210. See also Anemia
acceptable hemoglobin concentration, 482
acute coronary syndrome, 484
American Society of Anesthesiology guidelines for, 219
chronic ischemic heart disease patient, 484
in coagulopathy, 316–18
critical hemoglobin concentration, 482
early severe sepsis, 484
effect on tissue oxygenation, 224–6
hyperoxia in, 454–5
THI, patient with, 484–5
Red cell alloantibodies, 33
IgG antibodies, 33
IgM antibodies, 33
specificities associated with hemolyis, 34t
Red cell apheresis, 5–6
Red-cell components
irradiation of, 18
for IUT/exchange transfusion, 19–20
leukocyte-depleted, volume and hemoglobin content of, 14f
preparation of, 13, 14f
storage of, 15
Red cell-free crystalloidal solution, infusion of, 450
Red cell loss, reduction of, 482. See also Anemia
Red cell salvage, in cardiac operations, 464
Red cell substitutes, 7
Red Cross, 5
Reduced red cell production and anemia, 481
Reduced red cell survival and anemia, 480
Reduced surgical time, 433
Regional anesthesia, 425
Relative iron deficiency, 350
Renal anemia
ESAs therapy for, 357
clinical use of, 359–60
complications of, 362
dialysis adequacy and response to, 360
failure in response, 360–61
types of, 358–9
iron therapy for, 362–4
Renal dialysis patients, iron therapy in, 350
Renal dysfunction, in aprotinin treated patients, 271–2
Renal failure, 33, 35–6
Renal impairment, and anemia, 75
Renin-angiotensin-aldosteron system (RAAS), 159
Reopening for bleeding, clinical relevance, 409–11
Replacement donors, 5
Residual risk, 25–6
calculation of, 26
data on, 26–7
other countries, 27t
UK data, 27t
definition of, 26
Resuscitation
controlled hypotension use in, 436
of patients, use of HES solutions for, 318
Resuscitation fluid
efficacy of, evaluation of, 179
hypertonic fluids as, See Hypertonic saline (HS) solutions, use of ideal resuscitation fluid, 179–80
use of, 179–80
The Resuscitation Outcomes Consortium (ROC), 188
Reticuloendothelial system (RES), 334
Retransfusion, of unwashed wound blood, 458–60
Rheological effect of red cells, 317
Rickettsia rickettsii (Rocky Mountain spotted fever), 23
Right mini-thoracotomy, 399–400
Rights movement and Jehovah’s Witnesses. See Jehovah’s Witnesses “Right to die” doctrine, 535, 537
Ringer’s lactate, use of, 112–13, 122–3
Robotic and video-assisted valve surgery, effect of, 399t
Rotational thromboelastometry (ROTEM), 256, 258–9
Routine coagulation testing, 256–7
limitations of, 257–8
10/30 rule, for transfusion, 296
SAFE (Saline vs Albumin Fluid Evaluation) study, 123, 168, 174
SALINE, 122
hypertonic, 113
normal, use of, 111–12
Schedule of optimal preoperative collection of autologous blood (SOP-CAB), 304
Screening program
effectiveness of, factors for, 24
incidence and prevalence of infectious diseases, 24–5
quality system, effectiveness of, 25
classification, role of, 25
screening assays, performance of, 25
stages of, 24
Second-level coagulation tests, 257
Seizure, ESAs causing, 362
Serious Hazards of Transfusion (SHOT) report, 31, 42
Serum ferritin, 235, 363
Serum lactate increase, effect of, 299
Severe anemia, oxygen transport in, 205
Sevoflurane, solubility of, 384
Sickle cell disease
indications for transfusion in, 75–6, 76t
and pregnancy, 76
Sickle pain, preventive therapy of, 76
Sigmoid mucosal tonometry. See Gastric mucosal tonometry
Skeletal muscle tissue oxygenation, HV role in, 455
Skeletonization of internal thoracic artery, 413–14
S-303 method, 62–3
Society’s Hospital Liaison Committees, 544
Sodium caprylate, 97
Sodium citrate, 4
Soluble contaminants, elimination of, 461
Soluble form of transferrin receptor (sTFR), 480
Soluble transferrin receptor, 363
Soluble transferrin receptor concentrations (sTFR), 480
Traumatic blood loss, causing anemia, 337
Traumatic brain injury (TBI), 484
patient with, 484–5
use of hypertonic fluids for, 184
TRICC trial, in RBC transfusion, 482–3
Tri(n-butyl)-phosphate, 89
Trivariant analysis, of blood loss, 305–6
True iron deficiency, ACD with, 339
Trypanosoma cruzi (Chagas disease), 23
Tumor necrosis factor-α (TNF-α), 233
Tween 80, 89
Ultrafiltration, in pediatric open-heart operations, 317
Unbalanced colloids, 162
Uncontrolled aortic hemorrhage, model for, 435
Unfractionated heparin (UFH), 409
Unique dog model, 412
United Kingdom data on residual risk of transfusion-transmitted viral infections, 27t
United States National Institutes of Health, 76
Univariant analysis, of blood usage, 303–4
Unwashed wound blood, retransfusion of, 458–60
Urea-linked gelatin, 114, 138, 160, 171
Uremia per se, 237
Uremic patients, heart in, 237
Vacuum-assisted venous drainage, use of, 401–2
Valve surgery, anemia risk in, 240–41
Valvular surgery, 398–401
Variant Creutzfeldt-Jakob disease (vCJD), 12, 19, 29
Vascular constriction, 412
Vascular surgery, cell salvage in, 465
Vasoconstriction development of, 440
hyperoxic ventilation induced, 454–5
Venofer®, 513, 515
Venous oxygen saturation (SvO₂), 206, 211–12
Videoscopie and robotic-assisted nonsternotomy approaches, 396–8
Viscoelastic whole blood test, 258
VISEP (Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis) study, 154
Volatile anaesthetics, usage of, 383
Volume replacement strategies, in surgical patient, 159, 164
balanced volume replacement strategy, 161–2
colloids, use of, 159
dextrans, 160
gelatins, 160–61
human albumin, 159–60
hydroxyethyl starch, 161
synthetic colloids, 160
crystalloids, use of, 159
goal of, 159
literature analysis on, 162–4
surgery and hypovolemia, 158–9
Volunteer donors, 5
Von Willebrand factor (VWF), 16, 63, 93, 138, 139f
von Willebrand’s disease, diagnosis, 321
Warfarin, 92
Warm mediastinal irrigation, 412–13
West Nile virus, 6, 23
Whole-blood collection, storage, and processing, 11, 12f
Whole-blood donations platelet components production from, 14f
processing of, 11
production of components from, 12f
Whole-blood filters, 12
Whole blood flow cytometry, 140
Whole-blood, from allogenic donor collection of, 11
storage of, 11
Whole fresh blood, 68
Window period, 26
World Health Organization (WHO) anemia definition by, 477
World War II, 4–5
Xenon solubility, in PFCs, 383
Yeast and transgenic plants, recombinant
Hb production, 370
Zika virus, 23–4
Zinc protoporphyrin (ZPP), 363